American Cancer Society
UBI Light Therapy from the American Cancer Society web page Quote from below:
“ Ultraviolet blood irradiation treatment is approved by the US Food and Drug Administration for treating T-cell lymphoma involving the skin. Clinical trials look promising for the treatment of immune system diseases such as multiple sclerosis, rheumatoid arthritis, lupus, rejection of transplanted organs, and graft-versus-host disease…).”
Excerpts from their site http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Light_Therapy.asp
Other common name(s): ultraviolet light therapy, UV, ultraviolet blood irradiation,
Scientific/medical name(s): phototherapy, ultraviolet phototherapy, photopheresis, extracorporeal photochemotherapy, photodynamic therapy
DESCRIPTION Light therapy involves the use of visible light or non-visible ultraviolet light to treat a variety of conditions.
OVERVIEW A special form of UV blood irradiation, called photopheresis or extracorporeal photochemotherapy, also inhibits T-cell lymphoma and may be helpful for other conditions..
UV blood irradiation. Proponents of UV blood irradiation claim that UV light exposure kills germs such as viruses, bacteria, and fungi inside the body, and that it neutralizes toxins in the blood. Some claim that when even a very small amount of UV-treated blood re-enters the circulatory system of the patient it stimulates the immune system and increases attacks against invaders, including cancer cells.
What is the history behind it? Interest in the relationship between light and health dates back centuries. All forms of light therapy now in use started during the 20th century. The first reports of ultraviolet blood irradiation date back to the 1930s.
What is the evidence? Ultraviolet blood irradiation treatment is approved by the US Food and Drug Administration for treating T-cell lymphoma involving the skin. Clinical trials look promising for the treatment of immune system diseases such as multiple sclerosis, rheumatoid arthritis, lupus, rejection of transplanted organs, and graft-versus-host disease (a complication related to bone marrow or stem cell transplants). Available scientific evidence does not support claims for alternative uses of UV blood irradiation.
Herrmann JJ, Roenigk HH Jr, Honigsmann H. Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9:1077-1088.
Ilhan O, Arat M, Arslan O, Ayyildiz E, Sanli H, Beksac M, Ozcan M, Gurman G, Akan H. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease. Transfus Apheresis Sci. 2004 Jun;30(3):185-7.
Knobler R, Girardi M. Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas.Annals of the New York Academy of Sciences. 2001. 941:123-38.
Marques MB. Tuncer HH. Photopheresis in solid organ transplant rejection. Journal of Clinical Apheresis 2006. 21(1):72-7.
Woltz P. Castro K. Park BJ. Care for patients undergoing extracorporeal photopheresis to treat chronic graft-versus-host disease: review of the evidence. Clinical Journal of Oncology Nursing 2006 Dec. 10(6):795-802.
“ Ultraviolet blood irradiation treatment is approved by the US Food and Drug Administration for treating T-cell lymphoma involving the skin. Clinical trials look promising for the treatment of immune system diseases such as multiple sclerosis, rheumatoid arthritis, lupus, rejection of transplanted organs, and graft-versus-host disease…).”
Excerpts from their site http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Light_Therapy.asp
Other common name(s): ultraviolet light therapy, UV, ultraviolet blood irradiation,
Scientific/medical name(s): phototherapy, ultraviolet phototherapy, photopheresis, extracorporeal photochemotherapy, photodynamic therapy
DESCRIPTION Light therapy involves the use of visible light or non-visible ultraviolet light to treat a variety of conditions.
OVERVIEW A special form of UV blood irradiation, called photopheresis or extracorporeal photochemotherapy, also inhibits T-cell lymphoma and may be helpful for other conditions..
UV blood irradiation. Proponents of UV blood irradiation claim that UV light exposure kills germs such as viruses, bacteria, and fungi inside the body, and that it neutralizes toxins in the blood. Some claim that when even a very small amount of UV-treated blood re-enters the circulatory system of the patient it stimulates the immune system and increases attacks against invaders, including cancer cells.
What is the history behind it? Interest in the relationship between light and health dates back centuries. All forms of light therapy now in use started during the 20th century. The first reports of ultraviolet blood irradiation date back to the 1930s.
What is the evidence? Ultraviolet blood irradiation treatment is approved by the US Food and Drug Administration for treating T-cell lymphoma involving the skin. Clinical trials look promising for the treatment of immune system diseases such as multiple sclerosis, rheumatoid arthritis, lupus, rejection of transplanted organs, and graft-versus-host disease (a complication related to bone marrow or stem cell transplants). Available scientific evidence does not support claims for alternative uses of UV blood irradiation.
Herrmann JJ, Roenigk HH Jr, Honigsmann H. Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9:1077-1088.
Ilhan O, Arat M, Arslan O, Ayyildiz E, Sanli H, Beksac M, Ozcan M, Gurman G, Akan H. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease. Transfus Apheresis Sci. 2004 Jun;30(3):185-7.
Knobler R, Girardi M. Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas.Annals of the New York Academy of Sciences. 2001. 941:123-38.
Marques MB. Tuncer HH. Photopheresis in solid organ transplant rejection. Journal of Clinical Apheresis 2006. 21(1):72-7.
Woltz P. Castro K. Park BJ. Care for patients undergoing extracorporeal photopheresis to treat chronic graft-versus-host disease: review of the evidence. Clinical Journal of Oncology Nursing 2006 Dec. 10(6):795-802.
